Sideroblastic anemias that are caused by SLC25A38 mutations are refractory to pyridoxine treatment, which is used to treat sideroblastic anemias caused by ALAS2 mutations that occur in the PLP binding region (Fernández-Murray et al., 2016). Here, ALAS2 is linked to sideroblastic anemia.